FDA approves Onureg (oral azacitidine) for the continued treatment of adults with acute myeloid leukaemia (AML)
Continued treatment with once daily oral azacitidine demonstrated an overall survival benefit in adults with AML who had achieved first complete remission in the QUAZAR AML-001 study, with a statistically significant improvement of nearly 10 months versus placebo.
Source:
PharmaTimes
SPS commentary:
A marketing authorisation application for oral azacitidine was filed for approval in the EU in June 2020.